It is not often that regulators, companies and investors meet in the same room, let alone discuss topics of mutual interest. But this was the setting for the fourth annual meeting of the industry group, European Biopharmaceutical Enterprises (EBE), and the European Medicines Agency (EMA) in London on 14 December.
